Letter from the CEO
Dr. Luc-André Granier
Advicenne was founded in 2007 on the simple premise that, if a treatment for a rare kidney disease is a possibility, it should be made a reality. Over a decade later, as we enter commercialization in Europe and expand our clinical trials in North America, this commitment still stands at the heart of what we do.
Advicenne was listed on the Euronext Paris stock exchange in December 2017 (ADVIC – FR0013296746). And we are pleased to announce that, as of mid-June 2019, shares of our company will be traded on Euronext Brussels, giving Advicenne cross-listed status on the two largest Euronext life sciences markets.
Our lead drug candidate, ADV7103, was granted orphan drug designation by the European Commision for the treatment of distal renal tubular acidosis (dRTA). Currently in Phase III clinical trials for this indication in the United States and Canada, ADV7103 was submitted for European marketing authorization in March of 2019.
If approved, ADV7103 will be the first authorized treatment for dRTA, a rare kidney disorder that occurs when the kidneys are unable to effectively remove the buildup of circulating acids in the blood, resulting in severe complications – particularly for pediatric patients.
ADV7103 was awarded the prestigious Prix Galien MedStartUp Award for Best Innovative Trial Design in 2018. The product is currently in European Phase III clinical trials for a second indication, cystinuria, a genetic disease characterized by cystine stones in the kidneys and bladder.
More information about dRTA and cystinuria, and the innovative products we have designed to treat them, can be found in the pages of our corporate website. And we encourage you to sign up using the contact form below for information regarding upcoming corporate presentations and other company news and events.
We are delighted to welcome you to the Advicenne family, and to share with you in the many promising developments of this exciting moment in our company’s history.
Dr. Luc-André Granier
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.
© 2019 Advicenne